|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients withmyeloproliferative neoplasms.
|
31697806 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
3D-CRT and IMRT groups had been analyzed by propensity score matching method, with sex, age, Karnofsky performance status, induction chemotherapy and tumor stage well matched.
|
31048664 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We first confirmed the selectivity of cell death induced by PKBH1 in tumor L5178Y-R cells and observed that calreticulin exposure increased when cell death increased.
|
31275386 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A retrospective <i>in vivo</i> study compared tumour response to NA CRT in normal weight (n=53) versus overweight/obese patients (n=148).
|
31171903 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous administration of F8-F8-Calr led to a tumor growth retardation, which could be further improved by combination with anti-PD1 antibody treatment.
|
30579890 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The 2 most common mutations, type 1 (52-bp deletion) and type 2 (5-bp insertion), account for 85% of CALR-mutated neoplasms.
|
31626697 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Necrosis or hemorrhage were unaltered in both tumors, but pFUS induced DNA strand breaks in tumor cells at PNP ≥6 MPa. pFUS at >4 MPa suppressed anti-inflammatory cytokines in B16 tumors. pFUS to 4T1 tumors decreased anti-inflammatory cytokines and increased pro-inflammatory cytokines and cell adhesion molecules. pFUS at 6 MPa increased calreticulin and alterations in check-point proteins along with tumoral and splenic immune cell changes that could be consistent with a shift towards an anti-TME. pFUS-induced TME alterations shows promise in generating anti-tumor immune responses, but non-uniform responses between tumor types require additional investigation to assess pFUS as a suitable anti-tumor therapy.
|
31530419 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutations of the multifunctional protein calreticulin (CALR) are recognised as one of the main driver alterations involved in the pathogenesis of Philadelphia negative myeloproliferative neoplasms (Ph<sup>-</sup> MPN) and also represent a major diagnostic criterion in the most recent World Health Organization classification of myeloid neoplasms.
|
30606612 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor tissue was obtained before initiating preop-CRT.
|
31516597 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Objective</b>: Emerging evidence suggests that calreticulin (CALR) has great impacts on the tumor formation and progression of various cancers, but the role of CALR remains controversial.
|
31632490 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In severe combined immunodeficiency mice injected with HL-60 cells, DADS inhibited the growth of tumour tissue and decreased CRT levels and increased C/EBPα in vivo.
|
30394654 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Given the specificity and reported high frequencies of the JAK2V617F, MPL and CALR mutations in this group of neoplasms, the diagnosis of these diseases should not be made on clinical and hematological characteristics alone but should include genetic screening of patients.
|
31208359 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We harnessed a retrospective cohort of primary (no = 152) and metastatic (no = 74) tumor samples from HGSC patients to investigate the CALR expression in relation with prognosis and function orientation of the tumor microenvironment.
|
31747968 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In line with in vitro findings, hampered tumor latency and retarded tumor growth in xenograft model corroborated IR and CRT co-mediated neuronal differentiation of NB.
|
30612140 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a novel approach to combination therapy, we show that sequential treatment with 5-FU or CRT followed by evofosfamide not only inhibits tumor growth of xenografts compared with 5-FU or CRT alone, but also significantly decreases the CC-IC fraction.
|
29476017 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-xenografted mouse experiments further showed that CRT knockdown suppressed tumor growth and lymphangiogenesis.
|
30053596 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ICD is accompanied by the translocation of calreticulin (CALR) from the ER lumen to the plasma membrane, which facilitates the transfer of tumor-associated antigens to dendritic cells.
|
29358668 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, knockdown of Ro60/SSA inhibited the growth of subcutaneous tumors in vivo.
|
29274781 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We concluded that pretreatment tumor thickness is an independent predictor for pCR of stage II/III rectal adenocarcinoma to the neoadjuvant CRT.
|
27672742 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2).
|
30327655 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The patient with SRUS had histological changes of SSA/p, suggesting a potential of tumor transformation in certain cases.
|
30510949 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients undergoing extended CRT were more likely to harbor larger initial tumor size (p = 0.04), baseline nodal metastases (cN+; p < 0.001) and higher tumor location (p = 0.02).
|
29217398 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, observed association between SSA/P with advanced conventional neoplasia (but not low-grade adenomas) suggests 2 distinct groups of patient predisposition, one with both advanced conventional and important serrated precursors (SSA/P) and the other largely restricted to nonadvanced conventional adenomas and HPs only.
|
28723863 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the translational part of the study, we will evaluate the hypothesis that the baseline apparent diffusion coefficient (ADC) values of diffusion weighted MRI and its evolution 2 weeks after start of CRT, for the whole tumor as well as for intra-tumoral regions, is prognostic for residual tumor on the hysterectomy specimen.
|
30223802 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CVA21 induced immunogenic apoptosis in bladder cancer cell lines, as evidenced by expression of the immunogenic cell death (ICD) determinant calreticulin, and HMGB-1 release and the ability to reject MB49 tumors in syngeneic mice after vaccination with MB49 cells undergoing CVA21 induced ICD.
|
29989024 |
2018 |